What is HC Wainwright's Forecast for PLRX FY2029 Earnings?

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce forecasts that the company will post earnings of $1.75 per share for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Pliant Therapeutics' current full-year earnings is ($3.65) per share.

A number of other analysts also recently weighed in on the stock. Oppenheimer reaffirmed a "market perform" rating on shares of Pliant Therapeutics in a report on Monday, February 10th. Royal Bank of Canada downgraded shares of Pliant Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $45.00 to $4.00 in a research note on Monday, February 10th. Canaccord Genuity Group reissued a "hold" rating and issued a $4.00 price objective (down previously from $43.00) on shares of Pliant Therapeutics in a research note on Monday, February 10th. Wells Fargo & Company downgraded shares of Pliant Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $41.00 to $4.00 in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. cut shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, February 10th. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Pliant Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $17.75.

Remove Ads

Pliant Therapeutics Stock Performance

PLRX traded down $0.25 on Wednesday, reaching $3.04. The company had a trading volume of 3,584,808 shares, compared to its average volume of 496,398. The company's fifty day moving average is $11.48 and its 200 day moving average is $12.58. Pliant Therapeutics has a fifty-two week low of $2.43 and a fifty-two week high of $18.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The stock has a market cap of $184.98 million, a P/E ratio of -0.91 and a beta of 1.03.

Institutional Investors Weigh In On Pliant Therapeutics

A number of large investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in shares of Pliant Therapeutics by 1.9% in the third quarter. State Street Corp now owns 1,402,730 shares of the company's stock valued at $15,725,000 after buying an additional 26,610 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pliant Therapeutics by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company's stock valued at $14,781,000 after buying an additional 31,221 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Pliant Therapeutics in the fourth quarter valued at $17,326,000. Franklin Resources Inc. lifted its stake in shares of Pliant Therapeutics by 0.5% in the fourth quarter. Franklin Resources Inc. now owns 1,045,577 shares of the company's stock valued at $13,770,000 after buying an additional 5,673 shares in the last quarter. Finally, Candriam S.C.A. lifted its stake in shares of Pliant Therapeutics by 8.0% in the fourth quarter. Candriam S.C.A. now owns 900,104 shares of the company's stock valued at $11,854,000 after buying an additional 66,888 shares in the last quarter. 97.30% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pliant Therapeutics

In other Pliant Therapeutics news, CEO Bernard Coulie sold 52,419 shares of the firm's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $587,092.80. Following the completion of the sale, the chief executive officer now directly owns 430,517 shares in the company, valued at approximately $4,821,790.40. This trade represents a 10.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Mike Ouimette sold 10,230 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total transaction of $112,427.70. Following the completion of the sale, the general counsel now owns 70,544 shares of the company's stock, valued at $775,278.56. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,855 shares of company stock worth $1,026,628 over the last three months. 6.40% of the stock is owned by company insiders.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.